Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.
Abstract: Methods for identifying compounds that modulate the ion channel activity of a Kir channel are provided. Methods for identifying compounds that selectively modulate the ion channel activity of specific types of Kir channels based on the turret region of a Kir channel are also provided. Methods for identifying compounds to treat conditions associated with abnormal ion channel activity are also provided. Compounds including purified antibodies and methods of making antibodies which bind to the turret region of a Kir channel are provided. Purified polypeptides including at least a portion of the turret region of a Kir channel and nucleic acid sequences encoding these polypeptides are also provided.
Abstract: A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo.
Abstract: This invention relates to a kit and a method for the collection and analysis of complex protein mixtures. More particularly, the invention relates to a kit comprising a single barrel filtration well or a multi-well filtration plate wherein each well comprises an upper filtration zone; a lower filtration zone; a conical flow director zone; and, an elution tip, wherein the upper filtration zone and the lower filtration zone are separated by a retainer ring disposed within the lower filtration zone. The upper filtration zone comprises an upper collection zone, a sponge zone, and a deep bed filtration zone; and, the lower filtration zone comprises the retainer ring, a supported hydrophilic membrane and a lower bed filtration media. When used with an array of selected buffer solutions, the multi-well filtration plate can provide accurate, automated, high-throughput protein analysis by affinity chromatography.
Type:
Grant
Filed:
September 9, 2011
Date of Patent:
July 21, 2015
Assignees:
OROCHEM Technologies, Inc., The Rockefeller University
Inventors:
Asha A. Oroskar, John P. LaCava, Michael Paul Rout, Anil R. Oroskar
Abstract: A unidirectional active microphone that includes a diaphragm, coil, and piezoelectric component. An electrical circuit provides amplification to the coil. The piezoelectric component produces unidirectional coupling between coil and diaphragm. The microphone is unidirectional in that the amplification is provided solely to the coil and is not transferred to the diaphragm.
Type:
Grant
Filed:
January 31, 2012
Date of Patent:
July 14, 2015
Assignee:
The Rockefeller University
Inventors:
Albert James Hudspeth, Tobias Reichenbach
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
May 19, 2015
Assignee:
The Rockefeller University
Inventors:
Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
Type:
Application
Filed:
December 10, 2012
Publication date:
April 23, 2015
Applicants:
The Rockefeller University, Sloan-Kettering Institute for Cancer Research
Inventors:
Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
Abstract: In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide.
Type:
Grant
Filed:
February 5, 2013
Date of Patent:
April 14, 2015
Assignee:
The Rockefeller University
Inventors:
Thomas Tuschl, John Pena, Pavol Cekan, Cherin Sohn, Sara H. Rouhanifard, Janos Ludwig
Abstract: Methods, apparatuses, and software for operating such apparatuses, for neuromodulation in a live mammalian subject, such as a human patient, provide for applying electrical energy to a target site in the nervous system of the subject using a signal comprising a series of pulses, wherein the inter-pulse intervals are varied using the output of a deterministic, non-linear, dynamical system comprising one or more system control parameters. In certain embodiments, the target site may be a site in the brain involved in generalized CNS (central nervous system) arousal. The dynamical system may be capable of exhibiting chaotic behavior.
Type:
Grant
Filed:
February 26, 2010
Date of Patent:
April 7, 2015
Assignees:
Intelect Medical, Inc., The Rockefeller University
Inventors:
Scott Kokones, Bradford Curtis Fowler, Donald Pfaff, Amy Wells Quinkert
Abstract: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.
Type:
Grant
Filed:
January 30, 2009
Date of Patent:
April 7, 2015
Assignee:
The Rockefeller University
Inventors:
Thomas P. Sakmar, Thomas Huber, Sourabh Banerjee
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: The invention provides methods and compositions useful in target sequence suppression, target sequence validation and target sequence down regulation. The invention provides polynucleotide constructs useful for gene silencing or RNA down regulation, as well as cells, plants and seeds comprising the polynucleotides. The invention also provides a method for using microRNA to silence a target sequence or to down regulate RNA.
Type:
Grant
Filed:
October 12, 2005
Date of Patent:
March 10, 2015
Assignee:
The Rockefeller University
Inventors:
Jose L. Reyes Taboada, Xiuren Zhang, Takashi Soyano, Nam-Hai Chua, Qi-Wen Niu, Shih-Shun Lin
Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
Type:
Application
Filed:
January 16, 2013
Publication date:
February 19, 2015
Applicant:
The Rockefeller University
Inventors:
Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen, Jian-Kang Jiang
Abstract: The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
Type:
Grant
Filed:
October 1, 2009
Date of Patent:
January 27, 2015
Assignee:
The Rockefeller University
Inventors:
Alexander Ploss, Matthew Evans, Charles Rice
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
Abstract: The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
January 20, 2015
Assignee:
The Rockefeller University
Inventors:
Thomas H. Tuschl, Markus Landthaler, Gunter Meister, Sebastien Pfeffer
Abstract: The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein.
Type:
Application
Filed:
December 12, 2013
Publication date:
December 25, 2014
Applicant:
The Rockefeller University
Inventors:
Robert Darnell, Kirk Jensen, Jernej Ule
Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.
Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
Type:
Application
Filed:
May 16, 2014
Publication date:
October 30, 2014
Applicant:
The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Yoshikatsu Kaneko, Falk Nimmerjahn